Last updated: November 4, 2026
Basic Care Omeprazole is an OTC delayed-release omeprazole product positioned as a low-cost private-label alternative to Prilosec OTC and other generic proton-pump inhibitors. Its commercial value depends less on active-ingredient exclusivity and more on manufacturing cost, enteric-release performance, shelf stability, package count, retailer economics, and consumer adherence.
The key formulation requirement is protection of omeprazole from gastric acid. The product therefore relies on an enteric barrier, alkaline microenvironment, moisture control, and validated delayed-release dissolution. Omeprazole compound patents have expired, and the product is exposed to broad generic competition. The main commercial opportunities are lower-cost packaging, differentiated dosage forms, high-count value packs, adherence-oriented bundles, and alternate delivery technologies that preserve OTC regulatory simplicity.
What is Basic Care Omeprazole?
Basic Care Omeprazole is an Amazon/private-label OTC proton-pump inhibitor product containing omeprazole in a delayed-release oral dosage form. The typical strength is 20 mg omeprazole, generally administered once daily for frequent heartburn under the applicable OTC labeling.
| Attribute |
Commercial assessment |
| Active ingredient |
Omeprazole |
| Typical strength |
20 mg |
| Dosage form |
Delayed-release tablet or capsule presentation, depending on product version |
| Therapeutic class |
Proton-pump inhibitor |
| Main indication |
Frequent heartburn |
| Regulatory route |
FDA-approved OTC omeprazole labeling and generic/authorized private-label manufacturing |
| Retail position |
Value-priced, retailer-controlled brand |
| Primary competitors |
Prilosec OTC, generic omeprazole, Walgreens and CVS private labels, Target Up&Up, Walmart Equate |
| Patent status |
Core omeprazole composition and early formulation patents are expired |
| Main technical risk |
Failure of enteric protection, dissolution variability, moisture ingress, or stability degradation |
Basic Care is not generally marketed as an innovative molecule or proprietary drug-delivery system. Its differentiation is commercial execution: price, availability, count size, search placement, and retailer margin.
What excipients are used in Basic Care Omeprazole?
The formulation strategy for omeprazole is built around acid protection and controlled release. Exact inactive-ingredient lists can vary by manufacturer, dosage form, site, and product revision. Public labels for omeprazole delayed-release products commonly use the following excipient classes.
| Excipient class |
Typical function |
Commercial and technical relevance |
| Alkaline buffering agents |
Protect omeprazole from acid during processing and storage |
Critical because omeprazole degrades rapidly in acidic environments |
| Sugar spheres or microcrystalline cores |
Provide a substrate for drug layering in pellet or multiparticulate systems |
Support uniform drug distribution and controlled coating |
| Hypromellose |
Binder, film former, or seal coat |
Helps separate the drug layer from acidic enteric polymers |
| Povidone or related binders |
Improve granulation and drug-layer adhesion |
Supports manufacturing robustness |
| Methacrylic acid copolymers |
Enteric coating that dissolves at higher intestinal pH |
Determines delayed-release performance |
| Triethyl citrate, polyethylene glycol, or similar plasticizers |
Improve coating flexibility |
Reduces cracking and defects during processing |
| Talc or other anti-tacking agents |
Prevent coating-particle adhesion |
Improves coating yield and process efficiency |
| Titanium dioxide or iron oxides |
Opacifier or colorant |
Supports product identification and light protection |
| Magnesium stearate or comparable lubricants |
Improve tablet compression and ejection |
Excessive use can affect wetting and dissolution |
| Colloidal silicon dioxide |
Flow aid and moisture-management support |
Improves powder handling and blend uniformity |
| Gelatin or hypromellose capsule shell |
Capsule structure |
Relevant where the product uses delayed-release pellets in a capsule |
| Printing inks |
Product identification |
Important for supply-chain traceability and counterfeit control |
Why does omeprazole require an enteric coating?
Omeprazole is acid-labile. Exposure to gastric acid can degrade the active ingredient before it reaches the intestine, where proton-pump inhibition occurs. An enteric coating delays release until the dosage form encounters a higher-pH environment.
The formulation has two separate protection problems:
- The drug must be protected from gastric acid after administration.
- The drug must be protected from acidic excipients, residual moisture, and low-pH microenvironments during manufacturing and storage.
An alkaline core or subcoating is therefore as important as the outer enteric film. A formulation with a strong enteric polymer but poor internal buffering can still show potency loss or dissolution failure.
What excipient properties matter most?
The most important excipient variables are pH, moisture content, particle size, coating permeability, polymer grade, plasticizer level, and storage compatibility.
A commercial developer would normally prioritize:
- Low-moisture excipients
- Consistent alkaline reserve
- Narrow particle-size distribution
- High-quality enteric polymer dispersion
- Low coating-defect rates
- Robust resistance to gastric-acid exposure
- Rapid release after intestinal-pH exposure
- Compatibility with high-speed coating and packaging equipment
The formulation should be evaluated through acid-stage dissolution, buffer-stage release, accelerated stability, photostability, moisture-challenge studies, and package-integrity testing.
What formulations are protected by omeprazole patents?
The principal historical patent strategies for omeprazole covered the molecule, pharmaceutical salts, alkaline formulations, enteric-coated dosage forms, multiparticulate systems, and methods of treating acid-related disorders.
The core composition-of-matter protection for omeprazole has expired. Early AstraZeneca/AB Hässle patent families supported the original Prilosec franchise, but those rights no longer create a general barrier to Basic Care Omeprazole or other generic products.
Later patents historically addressed:
- Enteric-coated pellets
- Buffered omeprazole formulations
- Oral dosage forms with improved stability
- Specific coating polymers and subcoats
- Pediatric or sprinkle formulations
- Methods of treating gastroesophageal reflux disease
- Formulations combining omeprazole with antacids or other active ingredients
The practical patent position is now fragmented. A competitor may still obtain patents on a new delivery system, manufacturing process, combination product, or specific formulation, but those rights would not restore exclusivity to conventional 20 mg delayed-release omeprazole.
When does omeprazole lose exclusivity?
Omeprazole lost meaningful small-molecule exclusivity years ago. The original U.S. product, Prilosec, received FDA approval in the late 1980s. Its core patent protection and associated regulatory exclusivities expired before the current OTC generic market developed.
| Exclusivity category |
Status for conventional omeprazole |
| Composition-of-matter patent |
Expired |
| Original prescription product exclusivity |
Expired |
| Conventional delayed-release formulation protection |
Expired or no longer commercially blocking |
| OTC Prilosec exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Established |
| Current commercial barrier |
Manufacturing, quality, retailer access, and price rather than molecule patent rights |
No biologic or biosimilar framework applies. Omeprazole is a chemically synthesized small molecule, and Basic Care is exposed to ANDA-based generic competition rather than biosimilar substitution.
What is the Orange Book status of Basic Care Omeprazole?
Basic Care Omeprazole is generally understood as a private-label generic or authorized commercial product rather than an originator NDA product with a standalone patent estate. The Orange Book lists FDA-approved products and, where applicable, associated patents and exclusivity. It does not create a new patent position for a retailer brand merely because the product is sold under a different trade name.[1]
The commercial implications are:
- The product is unlikely to have meaningful Orange Book patent protection of its own.
- Any relevant patent risk would normally arise from the underlying approved generic product, manufacturing process, or a third-party formulation patent.
- The product’s regulatory value comes from approved labeling, bioequivalence, manufacturing compliance, and supply continuity.
- A retailer can change suppliers without changing the consumer-facing brand, subject to FDA requirements and product-specific filings.
A precise Orange Book assessment must be tied to the product’s manufacturer, NDA or ANDA number, and dosage form. The Basic Care brand name alone does not establish a unique listing.
Which companies are challenging omeprazole patents?
Generic manufacturers challenged the original Prilosec patent estate during the prescription-generic transition. Historical participants in the omeprazole market included Apotex, Mylan, Lek, Teva, Sandoz, Dr. Reddy’s, Ivax, and other generic manufacturers.
Those challenges were commercially important during the launch of generic omeprazole but do not represent a current barrier to Basic Care. The market now operates under mature generic competition, with multiple manufacturers supplying omeprazole delayed-release products.
What is the current Paragraph IV risk?
Paragraph IV risk is limited for conventional omeprazole because the principal originator patents have expired. A Paragraph IV filing could still arise against a newer patent covering:
- A novel multiparticulate formulation
- A modified-release profile
- A combination product
- A pediatric delivery system
- A manufacturing process
- A new indication or dosing regimen
A conventional 20 mg delayed-release product using established excipient technology is more likely to face ordinary ANDA competition than a meaningful patent challenge.
What patent litigation affects Basic Care Omeprazole?
There is no widely recognized current patent litigation directed specifically at the Basic Care brand. Historical litigation surrounding Prilosec and generic omeprazole focused on patent validity, infringement, ANDA timing, and formulation claims.
The relevant litigation risks for a private-label product are indirect:
- The supplier may be sued over a formulation or process patent.
- The retailer may be named in a product-liability or false-advertising action.
- A contract manufacturer may face an injunction affecting supply.
- A newly launched delivery system may trigger patent litigation even though conventional omeprazole is unpatented.
Retailer-brand agreements should allocate responsibility for patent clearance, Paragraph IV notices, indemnification, recalls, regulatory correspondence, and supply interruption.
How strong is the patent estate for Basic Care Omeprazole?
The patent estate is weak for the conventional product and potentially meaningful only for differentiated delivery technology.
| Patent layer |
Strength |
Commercial impact |
| Omeprazole molecule |
None |
Does not block generic entry |
| Conventional 20 mg delayed-release product |
Low |
Easily competed with by approved generics |
| Basic enteric coating |
Low |
Widely used and difficult to monopolize broadly |
| Specialized multiparticulate system |
Moderate |
May support narrower claims |
| New combination product |
Moderate to high |
Depends on active ingredients and claim scope |
| Manufacturing process |
Moderate |
Can raise supplier-switching costs |
| Packaging and moisture barrier |
Low to moderate |
Usually protects implementation, not the market |
| Brand and retailer placement |
Commercially strong, legally separate from patent rights |
Can influence share despite weak patent protection |
A stronger IP strategy would focus on a non-obvious delivery or stability improvement that produces measurable performance advantages. Broad claims directed only to enteric-coated omeprazole would face substantial prior-art and obviousness pressure.
What commercial opportunities exist for excipients?
Lower-cost enteric coating systems
A supplier could target lower-cost methacrylic acid copolymers, plasticizers, and anti-tacking systems that reduce coating time, energy use, or defect rates. The commercial opportunity is strongest where the excipient package is a direct substitute and does not require a major regulatory change.
Improved moisture protection
Moisture is a major stability concern for omeprazole. Opportunities include:
- High-barrier blister packaging
- Desiccant-supported bottles
- Low-moisture coating systems
- Improved seal integrity
- Moisture-scavenging bottle components
- Lower-water manufacturing processes
Packaging improvements may produce greater commercial value than a new inactive ingredient because they can extend shelf life without materially changing the dosage form.
Multiparticulate products
Pellet-filled capsules and sprinkle products can support differentiated dosing and pediatric or swallowing-impaired use. The opportunity is technically stronger than a conventional tablet but has higher manufacturing and regulatory costs.
Fast-dispersing and easy-swallow formats
Potential products include:
- Orally disintegrating tablets
- Mini-tablets
- Sprinkle capsules
- Smaller delayed-release tablets
- Granules for administration with soft food
The core challenge is preserving acid protection after disintegration. A fast-dispersing format cannot release omeprazole in the stomach; it must disperse protected particles or enteric-coated micro-units.
Combination products
A retailer could evaluate omeprazole combinations with antacids or alginate systems. These products may provide faster symptom relief than omeprazole alone, which has a delayed onset. Combination products also create greater regulatory, stability, labeling, and patent complexity.
How does Basic Care Omeprazole compare with competing products?
| Product type |
Main advantage |
Main weakness |
Patent exposure |
| Basic Care Omeprazole |
Low price and retailer availability |
Limited brand differentiation |
Low |
| Prilosec OTC |
Brand recognition and consumer trust |
Higher price |
Originator estate largely expired |
| Store-brand generic omeprazole |
Comparable active ingredient and price |
Variable packaging and availability |
Low |
| Famotidine products |
Faster symptom relief |
Different mechanism and dosing profile |
Low to moderate |
| Esomeprazole |
Strong brand positioning and perceived potency |
Higher cost |
Core patents expired or limited |
| Lansoprazole |
Established OTC alternative |
Less retailer differentiation |
Low |
| Alginate-antacid products |
Rapid physical barrier effect |
Shorter duration and different use case |
Product-specific |
Basic Care competes primarily on price and convenience. It does not need a stronger molecule patent position to succeed, but it must maintain reliable quality and avoid stockouts.
What generic launch scenarios exist?
Base case: continued price competition
The most probable scenario is stable supply from several generic manufacturers, with price compression and retailer optimization. Margin depends on manufacturing scale, packaging cost, and fulfillment efficiency.
Upside case: premium value-pack strategy
A large-count package, such as a 42-, 84-, or 100-count configuration, can lower per-dose cost and increase basket size. This strategy works best with high search visibility and stable repeat purchasing.
Differentiation case: improved delivery format
A sprinkle, mini-tablet, or orally disintegrating presentation could command a premium if it solves a real administration problem. The product would need clear labeling and strong evidence that delayed release remains intact.
Downside case: supplier or quality disruption
A coating failure, dissolution deviation, recall, or manufacturing interruption can remove a private-label product from retail platforms quickly. Dual sourcing and validated site-transfer plans are therefore important commercial assets.
What licensing deals and manufacturing partnerships matter?
Basic Care-type products are usually supplied through private-label, contract-manufacturing, or authorized-generic arrangements rather than high-value molecule licenses. The most important deal terms concern:
- Exclusive or nonexclusive supply
- Minimum annual volumes
- Cost-down schedules
- Alternate-site qualification
- Regulatory ownership
- Stability-data access
- Recall allocation
- Patent indemnification
- Change-control approval
- Packaging and artwork ownership
For excipient companies, the best opportunity is often a formulation-support agreement with a generic manufacturer rather than a license directly with the retailer. The manufacturer controls the ANDA, process validation, scale-up, and FDA correspondence.
What FDA regulatory issues affect Basic Care Omeprazole?
FDA compliance depends on approved labeling, current good manufacturing practices, dissolution performance, stability, batch uniformity, and accurate Drug Facts presentation. Omeprazole delayed-release products must demonstrate that the dosage form resists acid exposure and releases the drug under intestinal conditions.
Regulatory risks include:
- Unapproved formulation changes
- Excipient substitution without appropriate assessment
- Failure to maintain bioequivalence
- Inadequate stability after packaging changes
- Unsupported claims of faster relief or superior efficacy
- Labeling that exceeds the approved OTC indication
- Manufacturing-site changes without appropriate FDA filing
- Inconsistent inactive-ingredient disclosure
An excipient substitution that appears minor can affect coating permeability, dissolution, stability, and bioequivalence. The lowest-risk commercial path is usually a supplier change within an established excipient class, supported by comparative performance and regulatory documentation.
Key Takeaways
- Basic Care Omeprazole is a value-oriented OTC omeprazole product, not a molecule with meaningful current patent exclusivity.
- The critical formulation technology is acid protection through alkaline buffering, drug layering, subcoating, and enteric coating.
- The strongest commercial opportunities are moisture control, lower-cost coating systems, high-count packages, dual sourcing, and patient-friendly delivery formats.
- Conventional omeprazole is exposed to mature generic competition and has limited Paragraph IV risk.
- Biosimilar risk does not apply because omeprazole is a small-molecule drug.
- Orange Book relevance depends on the underlying FDA application and supplier, not the Basic Care brand name alone.
- A differentiated multiparticulate, sprinkle, or fast-dispersing product could create greater commercial value than another conventional delayed-release tablet.
- Manufacturing reliability, packaging performance, and retail availability are more important than patent exclusivity for the current product.
FAQs
Is Basic Care Omeprazole the same as Prilosec OTC?
It contains the same active ingredient, omeprazole, when the labeled strength and dosage form are equivalent. Excipients, manufacturer, packaging, and quality-system controls may differ.
Can omeprazole be formulated without an enteric coating?
A conventional oral omeprazole product generally requires acid protection. Without an enteric barrier or an equivalent protective delivery system, gastric degradation can materially reduce performance.
Are omeprazole excipients patentable?
Individual excipients usually are not patentable as existing substances. A novel combination, coating architecture, manufacturing process, or delivery system may qualify for patent protection if it is new and non-obvious.
Does Basic Care Omeprazole have biosimilar competition?
No. Biosimilar rules apply to biological products. Omeprazole is a chemically synthesized small molecule and competes through generic drug pathways.
What is the best commercial improvement for an omeprazole private-label product?
The highest-probability improvements are lower-cost manufacturing, stronger moisture protection, reliable supply, larger count sizes, and an administration-friendly dosage form that preserves delayed release.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
- U.S. Food and Drug Administration. (2024). Drug facts and labeling requirements for over-the-counter products. https://www.fda.gov/drugs
- U.S. Food and Drug Administration. (2023). Prilosec OTC: Omeprazole delayed-release tablets, labeling information. https://www.accessdata.fda.gov
- National Library of Medicine. (2024). DailyMed: Omeprazole delayed-release capsules and tablets. https://dailymed.nlm.nih.gov
- U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
- European Medicines Agency. (2023). Assessment reports and product information for omeprazole-containing medicinal products. https://www.ema.europa.eu
